Pancreatic cancer has one of the bleakest survival rates in oncology. Just 13% of patients are alive five years after diagnosis, according to the National Cancer Institute’s SEER database, largely because the disease rarely causes noticeable symptoms until it has spread beyond the point where surgery can help. But a peer-reviewed study published in May 2025 suggests that artificial intelligence can read warning signs on routine CT scans more than a year before doctors would typically catch the disease, and a federally funded clinical trial is now testing whether that head start can actually save lives.
What the Mayo Clinic study found
The most concrete evidence comes from a collaboration led by Mayo Clinic researchers and published in the journal Gastroenterology. The team trained radiomics-based machine-learning models on CT scans that had been taken before patients were ever diagnosed with pancreatic cancer, then asked the models to identify subtle tissue changes invisible to the human eye.
Across 155 confirmed pancreatic cancer cases, the AI flagged abnormalities on scans obtained 3 to 36 months before clinical diagnosis. The median lead time was roughly 13 months. In a cancer where the difference between Stage I and Stage IV is often the difference between a shot at curative surgery and palliative care alone, a year of advance warning could be transformative.
The study was retrospective, meaning the researchers looked backward at scans that had already been collected rather than deploying the tool in real time. That distinction matters. Retrospective analyses can overstate real-world performance because the data is cleaner and the patient population more uniform than what clinicians encounter day to day. Still, the results were strong enough to attract federal attention.
A separate clue hiding in prescription records
Independent research published in Nature Communications found that measurable shifts in patients’ medication patterns, including new prescriptions for acid reflux drugs and diabetes medications, appeared one to two years before a pancreatic cancer diagnosis. The finding suggests the body produces detectable metabolic signals well before overt symptoms like jaundice or unexplained weight loss emerge.
These medication changes are correlations, not proof of causation. Millions of people start acid reflux or diabetes drugs every year without ever developing pancreatic cancer. But as a second data stream layered on top of imaging, prescription records could help machine-learning systems sharpen their predictions and reduce false alarms. No study has yet demonstrated that combination approach in a prospective setting.
The NCI trial designed to settle the question
The National Cancer Institute is now funding a prospective clinical trial built to test whether these retrospective findings hold up when applied to real patients in real time. The trial, formally called “A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals with a High-Risk of Developing Pancreatic Cancer,” or the AI-PACED study, targets a specific high-risk group: people with glycemically defined new-onset diabetes and an elevated ENDPAC score of 3 or higher.
That selection criteria is deliberate. Research has shown that sudden, unexplained blood sugar changes can be an early metabolic consequence of a hidden pancreatic tumor rather than the onset of ordinary Type 2 diabetes. By focusing on this population, the trial concentrates its resources where the baseline cancer risk is meaningfully higher than average, improving the odds of detecting a screening benefit within a feasible study size.
The protocol calls for AI-augmented CT evaluation, longitudinal follow-up, and biobanking of blood and tissue samples for future analysis. The NCI’s data science division has described the underlying Mayo research as federally supported work intended for clinical translation, signaling that this effort carries institutional backing from the National Institutes of Health rather than operating as a standalone academic project.
As of spring 2026, no interim results or performance metrics from AI-PACED have been publicly released. The trial is in its early stages, and it will likely be years before definitive data emerges.
Why skepticism is still warranted
The distance between a promising algorithm and a reliable screening program is considerable, and several unresolved problems apply across the field of AI-driven cancer detection.
An open-access systematic review of machine-learning models for pancreatic cancer risk prediction cataloged recurring weaknesses in published studies. Most rely on retrospective case-control or cohort designs prone to selection bias. Many suffer from data leakage, where information that would not be available in a true screening scenario inadvertently informs the model during training, inflating apparent accuracy. And few have undergone rigorous external validation, meaning they perform well on the datasets they were built on but may falter when exposed to new patient populations or different imaging equipment.
The Mayo study’s 155-case sample, while meaningful for a proof of concept, is too small to establish how the model performs across different racial and ethnic groups, hospital systems, and scanner types. Those breakdowns have not been publicly detailed. If the training data skewed toward one demographic, the algorithm could underperform for patients outside that group, a problem that has plagued AI tools in other areas of medicine.
Even if AI-PACED produces encouraging results, the trial’s narrow eligibility criteria mean its conclusions will apply most directly to people with new-onset diabetes and elevated ENDPAC scores. Roughly 40% of pancreatic cancer patients have no prior metabolic warning signs, according to population-level studies. Whether AI screening could work for that broader group, or whether it could ever be cost-effective at a population scale, remains an open question with no published economic analysis to guide it.
What about blood tests and other screening approaches?
AI-augmented imaging is not the only technology chasing earlier pancreatic cancer detection. Multi-cancer early detection blood tests, sometimes called liquid biopsies, are also under investigation. Companies developing these assays have reported the ability to detect cell-free DNA or protein biomarkers associated with multiple cancer types, including pancreatic cancer, from a single blood draw.
However, the U.S. Preventive Services Task Force has not recommended routine screening for pancreatic cancer in the general population using any method, citing insufficient evidence that current tools reduce mortality. The American Cancer Society similarly does not include pancreatic cancer in its general screening guidelines. For now, screening is generally reserved for individuals with strong family histories, known genetic mutations like BRCA2 or CDKN2A, or other established high-risk factors.
That context is important for understanding where AI fits. It is not replacing an existing screening standard; it is attempting to create one for a cancer that has never had a reliable early-detection tool.
Where this stands for patients right now
The most defensible reading of the evidence as of spring 2026 is this: AI has demonstrated a measurable ability to detect preclinical pancreatic cancer on historical CT scans, and federal agencies consider the signal strong enough to invest in a prospective trial. It has not yet shown, in real time, that such detection improves survival, reduces late-stage diagnoses, or does so equitably across patient populations.
People at elevated risk, particularly those with new-onset diabetes, a strong family history, or known genetic predispositions, may reasonably ask their doctors about ongoing research and whether they qualify for trials like AI-PACED. But they should also understand that AI-based pancreatic cancer screening remains experimental. No algorithm has been approved by the FDA for this purpose, and no professional society currently recommends it outside of a research setting.
The questions that will ultimately determine whether AI reshapes pancreatic cancer outcomes are not about pattern recognition. Algorithms have already proven they can find subtle signals. The harder questions are what happens next: whether earlier flags translate into curative surgeries rather than palliative care, whether false positives can be kept low enough to avoid doing more harm than good, and whether the benefits reach all patients, not just those who happen to match the demographics of a training dataset.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
